Preventing bone complications in advanced prostate cancer

Current Oncology

Volumn 17, Issue SUPPL. 2, 2010, Pages

  Luz, M A ^a   Aprikian, Armen G ^a  

^a MCGILL UNIVERSITY   (Canada)

Author keywords

Bone metastases; Prostate cancer; Skeletal complications

Indexed keywords

4 AMINO 7 TERT BUTYL 5 (4 CHLOROPHENYL)PYRAZOLO[3,4 D]PYRIMIDINE; ALKALINE PHOSPHATASE; ANDROGEN; ATRASENTAN; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; CHLORIDE SR 89; CILENGITIDE; CLODRONIC ACID; DASATINIB; DENOSUMAB; DOCETAXEL; ETIDRONIC ACID RE 186; IBANDRONIC ACID; LEXIDRONAM SAMARIUM SM 153; MITOXANTRONE; N (3 METHOXY 5 METHYL 2 PYRAZINYL) 2 [4 (1,3,4 OXADIAZOL 2 YL)PHENYL] 3 PYRIDINESULFONAMIDE; OSTEOCLAST DIFFERENTIATION FACTOR; PAMIDRONIC ACID; PHOSPHATE P 32; PLACEBO; PREDNISONE; RADIOISOTOPE; SARACATINIB; UNCLASSIFIED DRUG; ZOLEDRONIC ACID;

ADVANCED CANCER; ALKALINE PHOSPHATASE BLOOD LEVEL; ANDROGEN DEPRIVATION THERAPY; ARTICLE; BONE BIOPSY; BONE METASTASIS; BONE SCINTISCANNING; BONE TURNOVER; BREAST CANCER; CALCIUM BLOOD LEVEL; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CLINICAL TRIAL; DIAGNOSTIC ACCURACY; DRUG BIOAVAILABILITY; DRUG DOSE COMPARISON; EARLY DIAGNOSIS; HUMAN; JAW OSTEONECROSIS; KIDNEY DYSFUNCTION; KIDNEY FAILURE; OSTEOBLAST; OSTEOCLAST; OSTEOLYSIS; OSTEOPOROSIS; OVERALL SURVIVAL; PATHOGENESIS; PATHOLOGIC FRACTURE; PHYSICAL EXAMINATION; PROGRESSION FREE SURVIVAL; PROSTATE CANCER; QUALITY OF LIFE;

EID: 78149478784     PISSN: None     EISSN: 17187729     Source Type: Journal    
DOI: 10.3747/co.v17i0.722     Document Type: Article

References (51)

1. Ellison LF, Wilkins K. Cancer prevalence in the Canadian population. Health Rep 2009;20:7-19.
2. Wadhwa VK, Weston R, Mistry R, Parr NJ. Long-term changes in bone mineral density and predicted fracture risk in patients receiving androgen-deprivation therapy for prostate cancer, with stratification of treatment based on presenting values. BJU Int 2009;104:800-5.
3. Ibrahim T, Flamini E, Mercatali L, Sacanna E, Serra P, Amadori D. Pathogenesis of osteoblastic bone metastases from prostate cancer. Cancer 2010;116:1406-18.
4. Tantivejkul K, Kalikin LM, Pienta KJ. Dynamic process of prostate cancer metastasis to bone. J Cell Biochem 2004;91:706-17.
5. Lehr JE, Pienta KJ. Preferential adhesion of prostate cancer cells to a human bone marrow endothelial cell line. J Natl Cancer Inst 1998;90:118-23.
6. Ye XC, Choueiri M, Tu SM, Lin SH. Biology and clinical management of prostate cancer bone metastasis. Front Biosci 2007;12:3273-86.
7. Israeli RS, Ryan CW, Jung LL. Managing bone loss in men with locally advanced prostate cancer receiving androgen deprivation therapy. J Urol 2008;179:414-19.
8. Michaud LB. Managing cancer treatment-induced bone loss and osteoporosis in patients with breast or prostate cancer. Am J Health Syst Pharm 2010;67(suppl 3):S20-30.
9. Cook RJ, Coleman R, Brown J, et al. Markers of bone metabolism and survival in men with hormone refractory metastatic prostate cancer. Clin Cancer Res 2006;12:3361-7.
10. Rajarubendra N, Bolton D, Lawrentschuk N. Diagnosis of bone metastases in urological malignancies-an update. Urology 2010;:. [Epub ahead of print]
11. Saad F, Lipton A, Cook R, Chen YM, Smith M, Coleman R. Pathologic fractures correlate with reduced survival in patients with malignant bone disease. Cancer 2007:15:1860-7.
12. Inoue T, Segawa T, Kamba T, et al. Prevalence of skeletal complications and their impact on survival of hormone refractory prostate cancer patients in Japan. Urology 2009;73:1104-9.
13. Berruti A, Tucci M, Mosca A, et al. Predictive factors for skeletal complications in hormone-refractory prostate cancer patients with metastatic bone disease. Br J Cancer 2005;93:633-8.
14. Egerdie B, Saad F. Bone health in the prostate cancer patient receiving androgen deprivation therapy: a review of present and future management options. Can Urol Assoc J 2010;4:129-35.
15. Saylor PJ, Smith MR. Bone health and prostate cancer. Prostate Cancer Prostatic Dis 2010;13:20-7.
16. Rosen LS, Gordon D, Kaminski M, et al. Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase iii, double-blind, comparative trial. Cancer J 2001;7:377-87.
17. Rosen LS, Gordon D, Tchekmedyian S, et al. Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a phase iii, double-blind, randomized trial-the Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group. J Clin Oncol 2003;21:3150-7.
18. Saad F, Gleason DM, Murray R, et al. Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J Natl Cancer Inst 2004;96:879-82.
19. Ernst DS, Tannock IF, Winquist EW, et al. Randomized, double-blind, controlled trial of mitoxantrone/prednisone and clodronate versus mitoxantrone/prednisone and placebo in patients with hormone refractory prostate cancer and pain. J Clin Oncol 2003;21:3335-42.
20. Small EJ, Smith MR, Seaman JJ, Petrone S, Kowalski MO. Combined analysis of two multicenter, randomized, placebocontrolled studies of pamidronate disodium for the palliation of bone pain in men with metastatic prostate cancer. J Clin Oncol 2003;21:4277-84.
21. Dearnaley DP, Sydes MR, Mason MD, et al. A double-blind, placebo-controlled, randomized trial of oral sodium clodronate for metastatic prostate cancer (mrc PR05 trial). J Natl Cancer Inst 2003;95:1300-11.
22. Dearnaley DP, Mason MD, Parmar MK, Sanders K, Sydes MR. Adjuvant therapy with oral sodium clodronate in locally advanced and metastatic prostate cancer: long-term overall survival results from the mrc PR04 and PR05 randomised controlled trials. Lancet Oncol 2009;10:872-6.
23. Coleman RE. Risks and benefits of bisphosphonates. Br J Cancer 2008;98:1736-40.
24. Ross JR, Saunders Y, Edmonds PM, Patel S, Broadley KE, Johnston SR. Systematic review of role of bisphosphonates on skeletal morbidity in metastatic cancer. BMJ 2003;327:469. [Erratum in: BMJ 2004;328:384]
25. Heidenreich A, Elert A, Hofmann R. Ibandronate in the treatment of prostate cancer associated painful osseous metastases. Prostate Cancer Prostatic Dis 2002;5:231-5.
26. Heidenreich A, Ohlmann C, Olbert P, Hegele A. High dose ibandronate is effective and well tolerated in the treatment of pain and hypercalcaemia due to metastatic urological cancer [abstract 897]. Eur J Cancer 2003;1(suppl 5):S270.
27. Coleman RE, Purohit OP, Black C, et al. Double-blind, randomised, placebo controlled, dose-finding study of oral ibandronate in patients with metastatic bone disease. Ann Oncol 1999;10:311-16.
28. McClung MR, Lewiecki EM, Cohen SB, et al. Denosumab in postmenopausal women with low bone mineral density. N Engl J Med 2006;354:821-31.
29. Fizazi K, Lipton A, Mariette X, et al. Randomized phase ii trial of denosumab in patients with bone metastases from prostate cancer, breast cancer or other neoplasms after intravenous bisphosphonates. J Clin Oncol 2009;27:1564-71.
30. Fizazi K, Bosserman L, Gao G, Skacel T, Markus R. Denosumab treatment of prostate cancer with bone metastases and increased urine N-telopeptide levels after therapy with intravenous bisphosphonates: results of a randomized phase ii trial. J Urol 2009;182:509-15.
31. Averbuch SD. New bisphosphonates in the treatment of bone metastases. Cancer 1993;72(suppl 11):3443-52.
32. Fizazi K, Beuzeboc P, Lumbroso J, et al. Phase ii trial of consolidation docetaxel and samarium-153 in patients with bone metastases from castration-resistant prostate cancer. J Clin Oncol 2009;27:2429-35.
33. Venkitaramana R, Barbachanob Y, Dearnaleya DP, et al. Outcome of early detection and radiotherapy for occult spinal cord compression. Radiat Oncol 2007;85:469-72.
34. Chow E, Danjoux C, Wong R, et al. Palliation of bone metastases: a survey of patterns of practice among Canadian radiation oncologists. Radiother Oncol 2000;56:305-14.
35. Petrylak DP, Tangen CM, Hussain MH, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004;351:1513-20.
36. Tannock IF, de Wit R, Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004;351:1502-12.
37. Carducci MA, Saad F, Abrahamsson PA, et al. A phase 3 randomized controlled trial of the efficacy and safety of atrasentan in men with metastatic hormone-refractory prostate cancer. Cancer 2007;110:1959-66.
38. Dawson N, Payne H, Battersby C, Taboada M, James N. Health-related quality of life in pain-free or mildly symptomatic patients with metastatic hormone-resistant prostate cancer following treatment with the specific endothelin A receptor antagonist zibotentan (ZD4054). J Cancer Res Clin Oncol 2010;:. [Epub ahead of print]
39. Bradley DA, Daignault S, Ryan CJ, et al. Cilengitide (emd 121974, nsc 707544) in asymptomatic metastatic castration resistant prostate cancer patients: a randomized phase ii trial by the Prostate Cancer Clinical Trials Consortium. Invest New Drugs 2010;:. [Epub ahead of print]
40. Panju AH, Breunis H, Cheung AM, et al. Management of decreased bone mineral density in men starting androgen-deprivation therapy for prostate cancer. BJU Int 2009;103:753-7.
41. Diamond TH, Higano CS, Smith MR, Guise TA, Singer FR. Osteoporosis in men with prostate carcinoma receiving androgen-deprivation therapy: recommendations for diagnosis and therapies. Cancer 2004;100:892-9.
42. Smith MR, Eastham J, Gleason DM, Shasha D, Tchekmedyian S, Zinner N. Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer. J Urol 2003;169:2008-12.
43. Michaelson MD, Kaufman DS, Lee H, et al. Randomized controlled trial of annual zoledronic acid to prevent gonadotrophin releasing hormone agonist-induced bone loss in men with prostate cancer. J Clin Oncol 2007;25:1038-42.
44. Smith MR, McGovern FJ, Zietman AL, et al. Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer. N Engl J Med 2001;345:948-55.
45. Greenspan SL, Nelson JB, Trump DL, Resnick NM. Effect of once weekly oral alendronate on bone loss in men receiving androgen deprivation therapy for prostate cancer: a randomized trial. Ann Intern Med 2007;146:416-24.
46. Magno C, Anastasi G, Morabito N, et al. Preventing bone loss during androgen deprivation therapy for prostate cancer: early experience with neridronate. Eur Urol 2005;47:575-81.
47. Kanis JA, Johnell O, Oden A, Johansson H, McCloskey E. frax and the assessment of fracture probability in men and women from the UK. Osteoporos Int 2008;19:385-97.
48. Steiner MS, Patterson A, Israeli R, Barnette KG, Boger R, Price D. Toremifene citrate versus placebo for treatment of bone loss and other complications of androgen deprivation therapy in patients with prostate cancer [abstract 4597]. Proc Am Soc Clin Oncol 2004;22:. [Available online at: www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view& confID=26&abstractID=1594; cited June 19, 2010]
49. Smith MR, Malkowicz SB, Chu F, et al. Toremifene increases bone mineral density in men receiving androgen deprivation therapy for prostate cancer: interim analysis of a multicenter phase 3 clinical study. J Urol 2008;179:152-5.
50. Smith MR, Fallon MA, Lee H, Finkelstein JS. Raloxifene to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer: a randomized controlled trial. J Clin Endocrinol Metab 2004;89:3841-6.
51. Smith MR, Egerdie B, Hernàndez Toriz N, et al. Denosumab in men receiving androgen-deprivation therapy for prostate cancer. N Engl J Med 2009;361:745-55.